VERITAS Vision System provide surgeons with enhanced stability and control throughout the phacoemulsification process
Johnson & Johnson Vision has received the FDA 510(k) clearance and CE mark for its new-generation phacoemulsification device VERITAS Vision System.
VERITAS Vision System is a modular ophthalmic microsurgical system designed to aid anterior segment ophthalmic surgery (cataract surgery).
The system comprises advanced features and technologies that provide surgeons with enhanced stability and control throughout the phacoemulsification process.
Also, the new phacoemulsification system comes with advanced ergonomics that further enhance usability during cataract surgery.
Johnson & Johnson Vision clinical and medical affairs chief medical officer and global head Rajesh K Rajpal said: “While the phacoemulsification technique has been used successfully for decades, ease of use continues to be the unmet need with cataract surgeons.
“Every aspect of Johnson & Johnson Vision’s new VERITAS System was designed to give surgeons an excellent user experience optimising features for safety and efficiency, with improvements in two main areas: fluidics and ergonomics.”
The FDA clearance and CE mark for VERITAS Vision System further strengthen the company’s goal of meeting the unmet needs of eye care professionals and patients.
Last month, Johnson & Johnson Vision has secured FDA approval for its TECNIS EYHANCE6 and TECNIS EYHANCE TORIC II intraocular lens (IOL) to treat cataracts.
The company said that it leverages a unique combination of materials and design in creating its IOLs, and its TECNIS platform has been used for cataract treatment for two decades.
Johnson & Johnson Vision is a part of Johnson & Johnson Medical Devices Companies and aims to deliver advanced products and technologies that address unmet needs.